Wave Life Sciences Announces Post-Incretin Maintenance Trial Timeline and Extended Cash Runway
Wave Life Sciences (WVE) has provided updates regarding its clinical pipeline and financial position. The company plans to initiate a post-incretin maintenance trial in the fourth quarter, continuing its focus on advancing RNA medicines through proprietary chemistry and genetic insights. Financially, Wave reported an extended cash runway that is projected to last into the third quarter of 2028. This provides the company with significant liquidity to support its ongoing research and development efforts as it advances its oligonucleotide platform.
Tickers: $WVE